NCT02982590

Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus

Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus: A Prospective Randomized Outcome Blinded Study on the Size Reduction or Resolution of Left Ventricular Thrombus

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 27 (actual)
• Sponsor: Universiti Sains Malaysia · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare the novel oral anticoagulant apixaban with the standard therapy of warfarin on the size reduction or resolution of left ventricular thrombus over 3 months.

Detailed description

Current treatment for left ventricular thrombus is anti-coagulant or blood thinning agent known as warfarin. Recently at least three novel oral anticoagulant agents were used in the treatment of atrial fibrillation, pulmonary embolism and deep vein thrombosis (DVT). Novel oral anticoagulant drugs will require no blood taking for INR monitoring, hence less visit and more convenience to patients. Latest studies also showed lesser rate of bleeding as compared to warfarin and hence relatively safer.

Conditions

• Left Ventricular Thrombosis

Interventions

Type	Name	Description
DRUG	Apixaban 5 MG Oral Tablet [ELIQUIS]	Apixaban is licensed for treatment of deep vein thrombosis and pulmonary embolism. Hence, a good study drug for left ventricular thrombosis for possibility of a new indication.
DRUG	Warfarin Sodium	as controlled arm since warfarin is the standard therapy for LV thrombus

Timeline

• Start date: 2016-11-01
• Primary completion: 2018-11-01
• Completion: 2018-11-01
• First posted: 2016-12-05
• Last updated: 2021-07-08
• Results posted: 2021-07-08

Locations

1 site across 1 country: Malaysia